Comparative Pharmacology
Head-to-head clinical analysis: CLORAZEPATE DIPOTASSIUM versus KLONOPIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CLORAZEPATE DIPOTASSIUM versus KLONOPIN.
CLORAZEPATE DIPOTASSIUM vs KLONOPIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Binds to benzodiazepine site on gamma-aminobutyric acid type A (GABAA) receptors, enhancing GABA-mediated chloride ion influx, leading to neuronal hyperpolarization and decreased excitability.
Benzodiazepine that binds to GABA-A receptors at the benzodiazepine binding site, enhancing the effect of GABA and increasing chloride ion influx, leading to neuronal hyperpolarization and decreased neuronal excitability.
15-60 mg/day orally in divided doses 2-4 times daily; usual starting dose 15 mg at bedtime or 15 mg twice daily.
0.5 mg orally three times daily; maximum 20 mg/day
None Documented
None Documented
40-50 hours (clorazepate is a prodrug rapidly converted to nordiazepam); effective half-life of nordiazepam is 40-100 hours. Accumulation occurs with repeated dosing, leading to prolonged sedation in elderly or hepatic impairment.
30-40 hours in adults; prolonged in elderly (up to 50-80 hours) and hepatic impairment; clinical context: steady-state achieved in 5-10 days
Primarily renal (60-70% as oxazepam glucuronide and other metabolites), with 15-20% biliary/fecal elimination. Less than 1% excreted unchanged.
Renal excretion: ~50-70% as glucuronide metabolites, ~30% as unchanged drug (with enterohepatic recirculation); fecal: <2%
Category D/X
Category C
Benzodiazepine
Benzodiazepine